BRIEF-biOasis enters into a license agreement with Vaccinex Inc.

* biOasis Technologies Inc - Says under terms of agreement, Vaccinex will have right to commercialize its anti-Semaphorin 4D antibody technology
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.